Emerging studies indicate that the rise of t-NEPC prevalence is most likely a consequence of neuroendocrine transdifferentiation of adenocarcinoma under the selection pressure of anti-AR therapies [12]. The gene discussed is AR; the disease is adenocarcinoma.